JP2024524986A - Ｅｐ２アンタゴニスト化合物 - Google Patents

Ｅｐ２アンタゴニスト化合物 Download PDF

Info

Publication number
JP2024524986A
JP2024524986A JP2023579119A JP2023579119A JP2024524986A JP 2024524986 A JP2024524986 A JP 2024524986A JP 2023579119 A JP2023579119 A JP 2023579119A JP 2023579119 A JP2023579119 A JP 2023579119A JP 2024524986 A JP2024524986 A JP 2024524986A
Authority
JP
Japan
Prior art keywords
alkyl
ring
substituted
unsubstituted
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023579119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524986A5 (https=
Inventor
アレクアンダー ジェームズ ダンクトン，マシュー
ヴイ． セナトロフ，ジュニア，ウラジミール
アール． フリードマン，アーロン
ハワード オルソン，スティーブン
Original Assignee
レザボア ニューロサイエンス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レザボア ニューロサイエンス，インコーポレイテッド filed Critical レザボア ニューロサイエンス，インコーポレイテッド
Publication of JP2024524986A publication Critical patent/JP2024524986A/ja
Publication of JP2024524986A5 publication Critical patent/JP2024524986A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023579119A 2021-06-24 2022-06-24 Ｅｐ２アンタゴニスト化合物 Pending JP2024524986A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163214645P 2021-06-24 2021-06-24
US63/214,645 2021-06-24
PCT/US2022/034901 WO2022272060A1 (en) 2021-06-24 2022-06-24 Ep2 antagonist compounds

Publications (2)

Publication Number Publication Date
JP2024524986A true JP2024524986A (ja) 2024-07-09
JP2024524986A5 JP2024524986A5 (https=) 2025-07-02

Family

ID=84543943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579119A Pending JP2024524986A (ja) 2021-06-24 2022-06-24 Ｅｐ２アンタゴニスト化合物

Country Status (4)

Country Link
US (1) US20240182459A1 (https=)
EP (1) EP4359392A4 (https=)
JP (1) JP2024524986A (https=)
WO (1) WO2022272060A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4642450A2 (en) * 2022-12-28 2025-11-05 Reservoir Neuroscience, Inc. Ep2 antagonist compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201922256A (zh) * 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
CN114302746A (zh) * 2019-06-10 2022-04-08 Adc治疗有限公司 包含抗cd25抗体药物缀合物和另一剂的组合疗法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRIAN M. FOX ET AL.: "A Selective Prostaglandin E2 Receptor Subtype 2 (EP2) Antagonist Increases the Macrophage-Mediated C", JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, no. 13, JPN6026012988, 24 June 2015 (2015-06-24), pages 5256 - 5273, ISSN: 0005831101 *

Also Published As

Publication number Publication date
EP4359392A1 (en) 2024-05-01
EP4359392A4 (en) 2025-09-03
US20240182459A1 (en) 2024-06-06
WO2022272060A1 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
JP7672451B2 (ja) Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
ES2902676T3 (es) Aminotriazolopiridinas como inhibidores de cinasa
JP7657792B2 (ja) メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
CN107592861B (zh) 氟化赖氨酰氧化酶样2抑制剂及其用途
US9695183B2 (en) Substituted 7-azabicycles and their use as orexin receptor modulators
AU2014248763B2 (en) Substituted piperidine compounds and their use as orexin receptor modulators
JP6800885B2 (ja) イミダゾピラジン及びピラゾロピリミジン、並びにａｍｐａ受容体調節物質としてのこれらの使用
JP2020525525A (ja) Ｒｈｏ−関連プロテインキナーゼ阻害剤、ｒｈｏ−関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用
IL305119A (en) Tyk2 inhibitors and uses thereof
AU2022222472A1 (en) Tyk2 inhibitors and uses thereof
KR20190121404A (ko) 소마토스타틴 조절제 및 이의 용도
BR112015007731B1 (pt) Composto, composição farmacêutica que o compreende e uso do mesmo
CN108699006B (zh) 3-((杂-)芳基)-8-氨基-2-氧代-1，3-氮杂-螺-[4.5]-癸烷衍生物
EP4532485A1 (en) Tyk2 inhibitors and uses thereof
EP4267137A1 (en) Lactam (hetero)arylfusedpyrimidine derivatives as inhibitors of erbb2
JP2022540583A (ja) アデノシンａ２ａ受容体アンタゴニスト及びその使用
CN113412113A (zh) 氨基嗪酰胺
JP2024524986A (ja) Ｅｐ２アンタゴニスト化合物
WO2025114760A1 (en) Tyk2 inhibitors and uses thereof
EP4097084A1 (en) Collagen 1 translation inhibitors and methods of use thereof
WO2024226890A1 (en) Pyrazole 3h-imidazo(4,5-b)pyridine compounds and uses thereof
JP2024524981A (ja) Ｅｐ２アンタゴニスト化合物
CN117561262A (zh) 大环tak1抑制剂
JP2025530975A (ja) Ｉｒａｋ３結合剤としての置換イミダゾピラジン化合物
CN120344515A (zh) Pcsk9抑制剂及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250624

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260401